October 10, 2005 -- Despite meeting its endpoints, Celgene’s Revlimid was delayed for three months. The reason given was the uncertain teratogenicity (effects on the fetus) of the compound. But proving the absence of teratogenicity, like proving all negative findings, is a nearly impossible thing to do. However, with drug safety becoming ever more of an issue, the FDA is taking no chances. We look at the history of the drug, its very real benefits, and the effects of the slowdown on Celgene...
